Shukra Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh)
Shukra Pharmaceuticals Ltd · Outcome · 05 Nov 2026, 2:10 am
Shukra Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh) ■ Revenue: 4,420 (+652.1% YoY | +87.9% QoQ) ■ EBITDA: 1,870 (Loss to Profit YoY | -2.3% QoQ) ■ EBITDA Margin (%): 42.3 (Loss to Profit YoY | -3907 bps QoQ) ■ PAT: 1,271 (+434.5% YoY | -1.9% QoQ) ■ EPS (INR): 0.29 (+480.0% YoY | -3.3% QoQ) Shukra Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh) Segmental Performance Pharmaceutical segment ■ Revenue: 3,227 (+325.2% YoY | +34.1% QoQ) ■ EBIT: 1,506 (+3016.3% YoY | -19.0% QoQ) ■ EBIT Margin (%): 46.7 (+4031 bps YoY | -3062 bps QoQ) Medtech segment ■ Revenue: 1,251 ■ EBIT: 310 ■ EBIT Margin (%): 24.8
Original exchange filing (PDF)
More announcements from Shukra Pharmaceuticals Ltd
- Approval for Change of Name of Company on National Stock Exchange Limited dated 16th November 2026 · 17 Nov 2026
- Media Release · 05 Nov 2026
- Shukra Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 05 Nov 2026
- Reg 32 · 05 Nov 2026
- Unaudited financial results for the quarter ended 30th September 2026 · 05 Nov 2026
- SHUKRA PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 04-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 . · 04 Nov 2026
- The Board Meeting to be held on 03/11/2026 has been revised to 04/11/2026 The Board Meeting to be held on 03/11/2026 has been revised to 04/11/2026 · 04 Nov 2026
- SHUKRA PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 04-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 . · 04 Nov 2026
